Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Amgen 145 Study Shows No Difference In Risk Of Death In Aranesp-Treated Patients

This article was originally published in The Pink Sheet Daily

Executive Summary

Outcome could help to stabilize the use of erythropoiesis-stimulating agents in anemia patients in the oncology setting.

You may also be interested in...

EPO Aggressive Dosing May Be Curtailed By New Black Box Warning

Labeling for Amgen’s Aranesp and Epogen and Johnson & Johnson’s Procrit updated March 9 to include a black box warning on risk of mortality.

Amgen “Dear Doctor” Letter Warns Of Risk Of Death Associated With Aranesp

Letter follows release of data in patients receiving darbepoetin alfa who have anemia that is not due to concurrent chemotherapy, an off-label use.

Epoetin Alfa Increases Cardiovascular Risks When Targeting High Hemoglobin Levels, J&J Study Finds

Patients with chronic kidney disease, when treated with a more aggressive dose of Procrit, had a higher risk but no incremental improvement in quality of life.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts